Acrivon Therapeutics, Inc. Tax Withholding Paid on Stock Awards
Acrivon Therapeutics, Inc. (ACRV) reported Tax Withholding Paid on Stock Awards of $67.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-12
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $34.00K, a 64.95% decline year-over-year.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $33.00K, a 90.41% decline year-over-year.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $192.00K, a 70.32% decline year-over-year.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $117.00K, a 90.23% decline year-over-year.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $750.00K, a 70.24% decline from fiscal 2024.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $2.52M, a 94.29% increase from fiscal 2023.
- Acrivon Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $1.30M.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $34.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $67.00K 10-Q · filed 2026-08-12 | $259.00K derived: sum of 3 quarters · filed 2026-08-12 | $376.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $33.00K 10-Q · filed 2026-05-13 | $225.00K derived: sum of 2 quarters · filed 2026-05-13 | $342.00K derived: sum of 3 quarters · filed 2026-05-13 | $439.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $309.00K derived: sum of 2 quarters · filed 2026-03-19 | $406.00K derived: sum of 3 quarters · filed 2026-08-12 | $750.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $214.00K derived: sum of 2 quarters · filed 2026-08-12 | $558.00K 10-Q · filed 2025-11-13 | $1.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $441.00K 10-Q · filed 2026-08-12 | $1.09M derived: sum of 3 quarters · filed 2026-08-12 | $2.29M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $344.00K 10-Q · filed 2026-05-13 | $991.00K derived: sum of 2 quarters · filed 2026-05-13 | $2.19M derived: sum of 3 quarters · filed 2026-05-13 | $2.70M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.84M derived: sum of 2 quarters · filed 2026-03-19 | $2.35M derived: sum of 3 quarters · filed 2026-03-19 | $2.52M 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.71M derived: sum of 2 quarters · filed 2025-11-13 | $1.87M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $676.00K 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $166.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | $1.30M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |